Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells

Ras is frequently mutated in cancer, and novel therapies are being developed to target Ras signalling. To identify non-invasive surrogate markers of Ras activation and inhibition, we used31 P magnetic resonance spectroscopy (MRS) and investigated NIH 3T3 cells compared to a mutant ras transfected counterpart. The MR spectra indicated that phosphocholine (PC) levels increased significantly from 3 ± 2 fmol cell−1 in NIH 3T3 cells to 13 ± 4 fmol cell−1 in the transfected cells. The PC/NTP ratio increased significantly from 0.3 ± 0.1 to 0.7 ± 0.3. This could not be explained by either a faster proliferation rate or by alterations in cell cycle distribution. Both cell lines were treated with simvastatin, 17-AAG and R115777, agents which inhibit Ras signalling. Cell proliferation was inhibited in both cell lines. The spectrum of NIH 3T3 cells was not affected by treatment. In contrast, in the ras transfected cells growth inhibition was associated with an average 35 ± 5% drop in PC levels and a comparable drop in PC/NTP. Thus the MRS visible increase in phosphocholine is associated with Ras activation, and response to treatment is associated with partial reversal of phosphocholine increase in ras transfected cells. MRS might therefore be a useful tool in detecting Ras activation and its inhibition following targeted therapies. © 2001 Cancer Research Campaign

[1]  C. Bowden,et al.  Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Podo.  Tumour phospholipid metabolism , 1999, NMR in biomedicine.

[3]  J. Downward,et al.  Multiple Ras Effector Pathways Contribute to G1Cell Cycle Progression* , 1999, The Journal of Biological Chemistry.

[4]  J. Griffiths,et al.  Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis , 1999, British Journal of Cancer.

[5]  Z. Bhujwalla,et al.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.

[6]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[7]  K. Skorecki,et al.  Induction of Cytosolic Phospholipase A2 by Oncogenic Ras in Human Non-small Cell Lung Cancer* , 1997, The Journal of Biological Chemistry.

[8]  S. Williams,et al.  Immortalization and transformation are associated with specific alterations in choline metabolism. , 1996, Cancer research.

[9]  H. Degani,et al.  Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. , 1996, Anticancer research.

[10]  F. Podo,et al.  Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. , 1996, Anticancer research.

[11]  T. Wieder,et al.  Evidence for Phosphorylation of CTP:Phosphocholine Cytidylyltransferase by Multiple Proline-directed Protein Kinases (*) , 1996, The Journal of Biological Chemistry.

[12]  H. Degani,et al.  Simultaneous extraction of cellular lipids and water‐soluble metabolites: Evaluation by NMR spectroscopy , 1996, Magnetic resonance in medicine.

[13]  C. Kent,et al.  Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. , 1995, Archives of biochemistry and biophysics.

[14]  M. Diaz-Meco,et al.  Evidence for a Bifurcation of the Mitogenic Signaling Pathway Activated by Ras and Phosphatidylcholine-hydrolyzing Phospholipase C (*) , 1995, The Journal of Biological Chemistry.

[15]  D. Spandidos,et al.  Mutations of ras genes in human tumors (review). , 1995, International journal of oncology.

[16]  S. Ng,et al.  Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells , 1995, Molecular and cellular biology.

[17]  A. Cuadrado,et al.  Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells. , 1994, Oncogene.

[18]  Roger J. Davis,et al.  cPLA2 is phosphorylated and activated by MAP kinase , 1993, Cell.

[19]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[20]  H Degani,et al.  Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. , 1992, Biochimica et biophysica acta.

[21]  M. Leach,et al.  The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate. , 1991, British Journal of Cancer.

[22]  M. Diaz-Meco,et al.  Kinetic evidence of a rapid activation of phosphatidylcholine hydrolysis by Ki-ras oncogene. Possible involvement in late steps of the mitogenic cascade. , 1990, The Journal of biological chemistry.

[23]  C. Kent,et al.  Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. , 1990, The Journal of biological chemistry.

[24]  L. Beck,et al.  Inhibition of isoprenoid biosynthesis and the post-translational modification of pro-p21. , 1990, Journal of Biological Chemistry.

[25]  J. Lacal.  Diacylglycerol production in Xenopus laevis oocytes after microinjection of p21ras proteins is a consequence of activation of phosphatidylcholine metabolism , 1990, Molecular and cellular biology.

[26]  C. Marshall,et al.  Stimulation of phosphatidylcholine hydrolysis, diacylglycerol release, and arachidonic acid production by oncogenic ras is a consequence of protein kinase C activation. , 1989, The Journal of biological chemistry.

[27]  S. Aaronson,et al.  Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene , 1987, Nature.